IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
NCT00523159
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Cell Carcinoma
Interventions
DRUG:
Endoxana, IMA901, Leukine
DRUG:
IMA901 and Leukine
Sponsor
Immatics Biotechnologies GmbH